⁠Dimitry Nakhla | Babylon Capital®
TWO days ago I suggested $MEDP becomes an interesting consideration at $330💵 (~9.5% below that day’s price)

Yesterday shares of $MEDP fell ~10%, reaching my target ✅

As I stated in the most recent analysis:

“As you can see, $MEDP appears to have attractive return potential if we assume >30x earnings, a valuation that may not be justified by its growth rate & one that’s subject to multiple compression if the growth rate slows (which is expected for 2025-2026 vs 2018-2023)

Today at $365.70💵 $MEDP appears to be a “hold”

I’d consider $MEDP closer to $330💵(~26.70x NTM EPS), or roughly 9.5% below today’s share price”
_______

Stay tuned for today’s updated valuation analysis on $MEDP 📝

#stocks #investing

A sober valuation analysis on $MEDP 🧘🏽‍♂️

•NTM P/E Ratio: 29.52x
•5-Year Mean: 30.15x

•NTM FCF Yield: 3.91%
•5-Year Mean: 3.98%

As you can see, $MEDP appears to be trading near fair value

Going forward, investors can receive ~2% MORE in earnings per share & ~2% LESS in FCF per share 🧠***

Before we get into valuation, let’s take a look at why $MEDP is a great business

BALANCE SHEET✅
•Cash & Short-Term Inv: $510.89M
•Long-Term Debt: $0

$MEDP has a great balance sheet & 3.51x FFO Interest Coverage Ratio

RETURN ON CAPITAL✅
•2019: 16.0%
•2020: 17.6%
•2021: 18.0%
•2022: 46.8%
•2023: 46.4%
•LTM: 41.5%

RETURN ON EQUITY✅
•2019: 15.3%
•2020: 19.0%
•2021: 20.7%
•2022: 36.6%
•2023: 59.8%
•LTM: 58.9%

$MED has strong return metrics, highlighting the financial efficiency of the business

REVENUES✅
•2018: $704.59M
•2023: $1.88B
•CAGR: 21.76%

FREE CASH FLOW✅
•2018: $140.56M
•2023: $502.80M
•CAGR: 29.0%

NORMALIZED EPS✅
•2018: $2.81
•2023: $8.92
•CAGR: 25.98%

SHARE BUYBACKS✅
•2018 Shares Outstanding: 36.91M
•LTM Shares Outstanding: 31.93M

By reducing its shares outstanding 13.5%, $MEDP increased its EPS by 15.6% (assuming 0 growth)

MARGINS✅
•LTM Gross Margins: 66.9%
•LTM Operating Margins: 18.8%
•LTM Net Income Margins: 16.7%

***NOW TO VALUATION 🧠

As stated above, investors can expect to receive ~2% MORE in EPS & ~2% LESS in FCF per share

Using Benjamin Graham’s 2G rule of thumb, $MEDP has to grow earnings at a 14.76% CAGR over the next several years to justify its valuation

Today, analysts anticipate 2024 - 2026 EPS growth over the next few years to be slightly less than (14.76%) required growth rate:

2024E: $11.83 (32.5% YoY) *FY Dec
2025E: $13.42 (13.5% YoY)
2026E: $15.43 (15.0% YoY)

$MEDP has a great track record of meeting analyst estimates ~2 years out, so let’s assume $MEDP ends 2026 with $15.43 in EPS & see its CAGR potential assuming different multiples

30x P/E: $462.90💵 … ~10.9% CAGR

29x P/E: $447.47💵 … ~9.3% CAGR

28x P/E: $432.04💵 … ~7.6% CAGR

27x P/E: $416.61💵 … ~5.9% CAGR

As you can see, $MEDP appears to have attractive return potential if we assume >30x earnings, a valuation that may not be justified by its growth rate & one that’s subject to multiple compression if the growth rate slows (which is expected for 2025-2026 vs 2018-2023)

Today at $365.70💵 $MEDP appears to be a “hold”

I’d consider $MEDP closer to $330💵(~26.70x NTM EPS), or roughly 9.5% below today’s share price

This is where I can reasonably expect ~11% CAGR assuming a more conservative 27x 2026 earnings estimates

#stocks #investing
___

𝐃𝐈𝐒𝐂𝐋𝐎𝐒𝐔𝐑𝐄‼️: 𝐓𝐡𝐢𝐬 𝐢𝐬 𝐍𝐎𝐓 𝐈𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐀𝐝𝐯𝐢𝐜𝐞. 𝐁𝐚𝐛𝐲𝐥𝐨𝐧 𝐂𝐚𝐩𝐢𝐭𝐚𝐥® 𝐚𝐧𝐝 𝐢𝐭𝐬 𝐫𝐞𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐯𝐞𝐬 𝐦𝐚𝐲 𝐡𝐚𝐯𝐞 𝐩𝐨𝐬𝐢𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐬𝐞𝐜𝐮𝐫𝐢𝐭𝐢𝐞𝐬 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐭𝐰𝐞𝐞𝐭.

𝐓𝐡𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐜𝐨𝐧𝐭𝐚𝐢𝐧𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐭𝐰𝐞𝐞𝐭 𝐢𝐬 𝐢𝐧𝐭𝐞𝐧𝐝𝐞𝐝 𝐟𝐨𝐫 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐩𝐮𝐫𝐩𝐨𝐬𝐞𝐬 𝐨𝐧𝐥𝐲 𝐚𝐧𝐝 𝐬𝐡𝐨𝐮𝐥𝐝 𝐧𝐨𝐭 𝐛𝐞 𝐜𝐨𝐧𝐬𝐭𝐫𝐮𝐞𝐝 𝐚𝐬 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 𝐚𝐝𝐯𝐢𝐜𝐞 𝐭𝐨 𝐦𝐞𝐞𝐭 𝐭𝐡𝐞 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐧𝐞𝐞𝐝𝐬 𝐨𝐟 𝐚𝐧𝐲 𝐢𝐧𝐝𝐢𝐯𝐢𝐝𝐮𝐚𝐥 𝐨𝐫 𝐬𝐢𝐭𝐮𝐚𝐭𝐢𝐨𝐧. 𝐏𝐚𝐬𝐭 𝐩𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞 𝐢𝐬 𝐧𝐨 𝐠𝐮𝐚𝐫𝐚𝐧𝐭𝐞𝐞 𝐨𝐟 𝐟𝐮𝐭𝐮𝐫𝐞 𝐫𝐞𝐬𝐮𝐥𝐭𝐬.

𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐜𝐨𝐧𝐭𝐚𝐢𝐧𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐭𝐰𝐞𝐞𝐭 𝐡𝐚𝐬 𝐛𝐞𝐞𝐧 𝐨𝐛𝐭𝐚𝐢𝐧𝐞𝐝 𝐟𝐫𝐨𝐦 𝐬𝐨𝐮𝐫𝐜𝐞𝐬 𝐛𝐞𝐥𝐢𝐞𝐯𝐞𝐝 𝐭𝐨 𝐛𝐞 𝐫𝐞𝐥𝐢𝐚𝐛𝐥𝐞, 𝐛𝐮𝐭 𝐢𝐬 𝐧𝐨𝐭 𝐠𝐮𝐚𝐫𝐚𝐧𝐭𝐞𝐞𝐝 𝐚𝐬 𝐭𝐨 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐞𝐧𝐞𝐬𝐬 𝐨𝐫 𝐚𝐜𝐜𝐮𝐫𝐚𝐜𝐲. - Dimitry Nakhla | Babylon Capital®
tweet

⁠Librarian Capital
British American Tobacco $BATS $BTI down 3.8%

This is likely related to how 26-Sep is the first day shares trade ex-dividend in London https://t.co/33Kh9RwLhK

"British American Tobacco: Fun While It Lasted? Looking Beyond Rally" $BATS $BTI

Shares have fallen back after a multi-month rally, and structural concerns may be returning in H2

cc: $MO $PM $IMB
https://t.co/axUW3tph51 https://t.co/nvliEMCCwf - Librarian Capital
tweet

⁠Librarian Capital
Bill Ackman: "Eric Adams ... deserve(s) the presumption of innocence. I do know that Eric loudly spoke the truth on the migrant problem .... Having witnessed the weaponization of our country's prosecutorial resources ... I am that much more skeptical" https://t.co/xvNZZKhnvY
tweet

⁠Librarian Capital
Bill Ackman: "Eric Adams ... deserve(s) the presumption of innocence. I do know that Eric loudly spoke the truth on the migrant problem .... Having witnessed the weaponization of our country's prosecutorial resources ... I am that much more skeptical when indictments are announced"
tweet

⁠Stock Analysis Compilation
Artisan Partners on Diageo $DGE LN

Thesis: Diageo, the world’s largest spirits company, offers long-term growth and cash generation despite near-term headwinds and market concerns over changing consumer habits

(Extract from their Q2 letter) https://t.co/ued6k0zXEt
tweet

⁠Ahmad Jivraj
Most academics and professionals can't help you beat the market.
YOU must do it yourself.

You HAVE to believe that the story is true.
Very few believe. https://t.co/pB6NEsutHP
tweet